{
    "clinical_study": {
        "@rank": "66974", 
        "arm_group": {
            "arm_group_label": "aleglitazar / digoxin", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This open-label, two-period, fixed-sequence study will investigate the pharmacokinetics and\n      safety of multiple doses of aleglitazar on a single dose of digoxin in healthy volunteers.\n      In period 1, volunteers will receive a single dose of digoxin, in period 2 volunteers will\n      receive multiple doses of aleglitazar and a single dose of digoxin. The anticipated time on\n      study treatment is one month."
        }, 
        "brief_title": "A Pharmacokinetics Study of Aleglitazar in Combination With Digoxin in Healthy Volunteers", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy volunteers, 18-55 years of age, inclusive\n\n          -  Body mass index (BMI) between 18.0 and 30.0 kg/m2 inclusive.\n\n          -  Females must be either surgically sterile or post-menopausal for at least one year\n             or, if they are of child-bearing potential, must use two acceptable methods of\n             contracepetion\n\n          -  Volunteer normally drinks no more than three cups of coffee/tea/caffeinated soft\n             drinks per day and is willing to stop drinking coffee/tea/caffeinated soft drinks\n             during the study\n\n        Exclusion Criteria:\n\n          -  Any clinically relevant abnormal laboratory test results at screening or on Day -1\n\n          -  Has taken any prescribed or herbal/over the counter medication within 2 weeks prior\n             to the first dosing\n\n          -  A history of clinically significant gastro-intestinal, cardiovascular,\n             musculoskeletal, endocrine, hematological, psychiatric, renal, hepatic,\n             bronchopulmonary or neurological conditions or lipid metabolism disorders.\n\n          -  Infection with human immunodeficiency virus (HIV), hepatitis B, hepatitis C\n\n          -  An average alcohol intake of more than 14 units per week\n\n          -  A known permanent or unexplained elevation of serum transaminases > 1.5 times the\n             upper limit of normal\n\n          -  A positive screen for drugs of abuse\n\n          -  Acute infection requiring treatment within 4 weeks prior to screening\n\n          -  Diagnosed or treated malignancy within the past 5 years"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01701739", 
            "org_study_id": "BP25562", 
            "secondary_id": "2012-002269-36"
        }, 
        "intervention": [
            {
                "arm_group_label": "aleglitazar / digoxin", 
                "description": "Multiple doses of aleglitazar", 
                "intervention_name": "aleglitazar", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "aleglitazar / digoxin", 
                "description": "Single dose of digoxin", 
                "intervention_name": "digoxin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Digoxin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Manchester", 
                    "country": "United Kingdom", 
                    "zip": "M13 9WL"
                }
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label, Two-period Fixed-sequence Study to Investigate the Effect of Multiple Doses of Aleglitazar on a Single Dose of Digoxin in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics: Area under the concentration time curve", 
                "safety_issue": "No", 
                "time_frame": "Approximately 1 month"
            }, 
            {
                "measure": "Pharmacokinetics: maximum plasma concentration", 
                "safety_issue": "No", 
                "time_frame": "Approximately 1 month"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01701739"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics: Elimination half-life", 
                "safety_issue": "No", 
                "time_frame": "Approximately 1 month"
            }, 
            {
                "measure": "Pharmacokinetics: Time to maximum plasma concentration", 
                "safety_issue": "No", 
                "time_frame": "Approximately 1 month"
            }, 
            {
                "measure": "Pharmacokinetics: Renal clearance", 
                "safety_issue": "No", 
                "time_frame": "Approximately 1 month"
            }, 
            {
                "measure": "Pharmacokinetics: Apparent volume of distribution", 
                "safety_issue": "No", 
                "time_frame": "Approximately 1 month"
            }, 
            {
                "measure": "Pharmacokinetics: Apparent clearance", 
                "safety_issue": "No", 
                "time_frame": "Approximately 1 month"
            }, 
            {
                "measure": "Pharmacokinetics: Amount excreted in the urine", 
                "safety_issue": "No", 
                "time_frame": "Approximately 1 month"
            }, 
            {
                "measure": "Pharmacokinetics: Fraction of drug excreted in urine", 
                "safety_issue": "No", 
                "time_frame": "Approximately 1 month"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2 months"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}